☰

Durgadevi Ravillah, Ph.D. - Publications

Affiliations: 
2013 University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States 
Area:
Pathology, Oncology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Blum AE, Venkitachalam S, Ravillah D, Chelluboyina AK, Kieber-Emmons AM, Ravi L, Kresak A, Chandar AK, Markowitz SD, Canto MI, Wang JS, Shaheen NJ, Guo Y, Shyr Y, Willis JE, et al. Systems Biology Analyses Reveal Hyperactivation of Transforming Growth Factor beta and JNK Signaling pathways in Esophageal Cancer. Gastroenterology. PMID 30768984 DOI: 10.1053/J.Gastro.2019.01.263  0.319
2014 Ravillah D, Mohammed A, Qian L, Brewer M, Zhang Y, Biddick L, Steele VE, Rao CV. Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis. The Journal of Pharmacology and Experimental Therapeutics. 348: 59-68. PMID 24218540 DOI: 10.1124/Jpet.113.208645  0.583
2014 Das DS, Tian Z, Ray A, Ravillah D, Song Y, Richardson PG, Oronsky B, Scicinski J, Chauhan D, Anderson KC. Anti-Myeloma Activity of a Novel Free Radical Inducer Rrx-001 Blood. 124: 4712-4712. DOI: 10.1182/Blood.V124.21.4712.4712  0.452
2014 Song Y, Das DS, Ray A, Ravillah D, Munshi NC, Chauhan D, Anderson KC. Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 in Multiple Myeloma Blood. 124: 419-419. DOI: 10.1182/Blood.V124.21.419.419  0.429
2014 Ray A, Das DS, Ravillah D, Song Y, Macri V, Brooks C, Rowinsky E, Richardson PG, Chauhan D, Anderson KC. SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis Blood. 124: 3441-3441. DOI: 10.1182/Blood.V124.21.3441.3441  0.378
2014 Das DS, Ravillah D, Ray A, Song Y, Munshi NC, Richardson PG, Chauhan D, Anderson KC. Anti-Myeloma Activity of a Novel Glutaminase Inhibitor CB-839 Blood. 124: 3439-3439. DOI: 10.1182/Blood.V124.21.3439.3439  0.457
2014 Das DS, Ravillah D, Ray A, Song Y, Richardson PG, Trikha M, Chauhan D, Anderson KC. Synergistic Anti-Myeloma Activity of a Proteasome Inhibitor Marizomib and IMiD® Immunomodulatory Drug Pomalidomide Blood. 124: 2099-2099. DOI: 10.1182/Blood.V124.21.2099.2099  0.469
2014 Ray A, Ravillah D, Das DS, Song Y, Nordström E, Lindberg J, Richardson PG, Chauhan D, Anderson KC. A Novel Alkylating Agent Melphalan Flufenamide Ethyl Ester Induces an Irreversible DNA Damage in Multiple Myeloma Cells Blood. 124: 2086-2086. DOI: 10.1182/Blood.V124.21.2086.2086  0.37
2013 Janakiram NB, Mohammed A, Ravillah D, Choi CI, Zhang Y, Desai D, Amin S, Rao CV. Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats. Oncology Reports. 30: 952-60. PMID 23708609 DOI: 10.3892/Or.2013.2483  0.581
2013 Ravillah D, Qian L, Brewer M, Zhang Y, Biddick L, Madka V, Patlolla JMR, Mohammed A, Steele V, Rao CV. Abstract 4392: Targeting HADC-2: Chemopreventive effect of OSU-HDAC42 on rat colon carcinogenesis and APCmin/+ Mice intestinal tumorigenesis. Cancer Research. 73: 4392-4392. DOI: 10.1158/1538-7445.Am2013-4392  0.545
2010 Janakiram NB, Mohammed A, Ravillah D, Choi CI, Zhang Y, Desai D, Amin S, Rao CV. Abstract A35: Chemoprevention of colon carcinogenesis in F344 rats by Se,Se′‐1,4‐phenylenebis(1,2‐ethanediyl)bis‐isoselenourea (PBISe) a novel analog of PBIT, an iNOS inhibitor Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-A35  0.578
Show low-probability matches.